- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Promoting Equitable Access to Telemedicine During the COVID-19 Crisis
The authors of a Clinical research article in the January 2021 Health IT issue of The American Journal of Managed Care® discuss their findings and suggestions for making telehealth access more equitable for all.
Even before the coronavirus disease 2019 (COVID-19) pandemic prompted a sweeping shift toward telemedicine instead of in-person care, technological innovations were not reaching all patient populations evenly, creating a “digital divide” between those with access and those without. Understanding these disparities and ensuring more equitable use of telemedicine has become even more imperative during the pandemic.
On this episode of Managed Care Cast, we’re talking with 2 coauthors of an Original Research article published in our January Health IT special issue. The study, “Differences in the Use of Telephone and Video Telemedicine Visits During the COVID-19 Pandemic,” describes patterns of telemedicine visits by patients’ race, ethnicity, age, and language amid the pandemic in Spring 2020.
The authors joining us are Dr Jorge A. Rodriguez and Dr Ishani Ganguli, of Harvard Medical School and Brigham and Women’s Hospital in Boston.
Listen above or through one of these podcast services:
Read more:
Differences in the Use of Telephone and Video Telemedicine Visits During the COVID-19 Pandemic
Barriers to Accessing Online Medical Records in the United States
Addressing Evolving Patient Concerns Around Telehealth in the COVID-19 Era
Patient Experience After Modifying Visit Delivery During the COVID-19 Pandemic
Variable Long COVID Definitions Create Hurdles in Care, Research
August 12th 2025There is a need to consolidate various long COVID definitions to establish a standardized definition that ensures consistent recognition, documentation, diagnosis, and treatment, according to new research.
Read More
Updated mRNA Vaccines Against JN.1 Show Strong Safety Signal in Real-World Data
July 31st 2025A nationwide Danish cohort study demonstrated no increased risk of serious adverse events following vaccination with JN.1-updated mRNA COVID-19 vaccines, reinforcing their safety profile and supporting continued use in high-risk populations amid ongoing viral evolution.
Read More
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More
